Parth Patwari
Seminars
Tuesday 17th March 2026
Anti-CD38 Plasma-Cell Depletion in IgA Nephropathy: 2-Year Clinical Insights & the Case for Durable, Finite Dosing
12:30 pm
- Reviewing of 2-year follow-up data demonstrating sustained proteinuria reduction and eGFR stabilization after limited antiCD38 dosing
- Mechanistic rationale for targeting long-lived plasma cells to achieve durable immunologic and clinical remission
- Clinical and practical implications of finite treatment duration versus chronic dosing in IgA nephropathy management
- Broader applicability of anti-CD38 approaches across antibody-mediated kidney diseases and future development considerations
